Black Diamond Therapeutics
Develops brain-penetrant therapies for EGFR-mutant lung cancer and glioblastoma.
Something off on this page? Send us feedback.
Profile
Develops brain-penetrant MasterKey therapies through its MAP discovery engine. Silevertinib, an EGFR inhibitor for EGFR-mutant lung cancer and glioblastoma, is its lead clinical program; the company operates one clinical-stage segment with no approved commercial product.
Develops brain-penetrant MasterKey therapies for mutation-defined cancers through its MAP discovery engine. Rather than create a separate compound for each mutation, it designs compounds to address mutation families, overcome resistance, limit wild-type-mediated toxicity, and reach central nervous-system disease. Its lead clinical program, silevertinib, is a fourth-generation EGFR inhibitor for EGFR-mutant non-small cell lung cancer and glioblastoma.
Centered in Cambridge, Massachusetts, operations are managed as one clinical-stage segment, without an approved commercial product. The pipeline was narrowed after BDTX-4933 was licensed to Servier, which assumed development and worldwide commercialization responsibility. Progress depends on clinical-trial execution, regulatory approval, third-party development support, and capital or partnerships.
Company facts
Key statistics
Year to date −10.4% · Average volume (30d) 609.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jan 16, 2026 | Piper Sandler | Reiterate | Overweight | $12 | $8 | |
| Dec 4, 2025 | Guggenheim | Downgrade | Buy | Neutral | ||
| Oct 15, 2025 | Stifel Nicolaus | Target | $8 | |||
| Sep 3, 2025 | Guggenheim | Target | $8 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.20 | −$0.17 | +13.0% | — | — | — | +1.56% |
| Aug 5, 2026Q2 FY26 | −$0.20 | −$0.17 | +13.0% | $5.6M | — | — | +7.26% |
| May 7, 2026Q1 FY26 | −$0.18 | −$0.16 | +11.1% | $25.0M | — | — | +9.93% |
| Mar 16, 2026Q4 FY25 | −$0.18 | −$0.14 | +22.2% | $9.4M | — | — | +1.83% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $70.0M | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $70.0M | −$86.0K | $0 | $0 | −$27.0K | $0 | |
| Operating income | $54.5M | −$13.4M | −$11.0M | −$17.6M | −$11.3M | −$12.1M | |
| Net income | $56.5M | −$10.6M | −$8.5M | −$15.1M | −$9.0M | −$9.9M | |
| Diluted EPS | $0.98 | −$0.19 | −$0.15 | −$0.26 | −$0.16 | −$0.17 | |
| Gross margin | 100.0% | — | — | — | — | — | |
| Operating margin | 77.9% | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $70.0M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $110.5M · Total debt $17.0M · Total assets $125.0M · Shareholders' equity $96.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 57.30M · Float 46.02M · 80.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.56M | 18.43% | 13F | May 15, 2026 |
| Ryan Wilder | 5.03M | 8.90% | 13G | Nov 14, 2024 |
| Nea Management Company, LLC | 4.45M | 7.76% | 13F | May 15, 2026 |
| BlackRock, Inc. | 3.84M | 6.70% | 13G | Jul 27, 2026 |
| Biotech Growth N V · 10 percent owner | 2.73M | 4.77% | Form 4 | Mar 20, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- AstraZeneca (ADR)
Established EGFR-mutant NSCLC therapy, including CNS-active osimertinib
- Johnson & Johnson
First-line EGFR-mutant NSCLC regimen with brain-penetrant lazertinib
- ArriVent BioPharma
Brain-penetrant EGFR inhibitor program for uncommon NSCLC mutations
- ORIC Pharmaceuticals
Brain-penetrant EGFR inhibitor program for exon 20 and atypical mutations
- Cullinan Therapeutics
Next-generation EGFR exon 20 inhibitor for mutation-defined NSCLC
- Summit Therapeutics
Post-TKI EGFR-mutant NSCLC regimen with ivonescimab plus chemotherapy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics | $2.23 | 0.00% | $127.8M | — | — | — | — |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| ArriVent BioPharma | $30.17 | −0.17% | $1.41B | — | — | — | — |
| ORIC Pharmaceuticals | $13.24 | +0.08% | $1.37B | — | — | — | — |
| Cullinan Therapeutics | $21.70 | +0.09% | $1.33B | — | — | — | — |
| Summit Therapeutics | $13.71 | +0.03% | $10.95B | — | — | — | — |
| Median | 27.7 | 18.8 | 5.3 | +6.5% |